|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date26 Sep 2022 |
K-232 clinical pharmacology study in healthy adult males
K-232 clinical pharmacology study in healthy adult males
K-232 phase 3 comparative study compared to brimonidine ophthalmic solution in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OH)
100 Clinical Results associated with ROCK1 x α2A-AR
100 Translational Medicine associated with ROCK1 x α2A-AR
0 Patents (Medical) associated with ROCK1 x α2A-AR